

Kesimpta - Dosing - KESIMPTA Sensoready Pen - HCP

[Prescribing information](#)

Image



Image



KESIMPTA®▼ (ofatumumab) Sensoready Pen: self-injection video - healthcare professional instructions


KESIMPTA is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.¹

For full safety information, please refer to the KESIMPTA Summary of Product Characteristics (SmPC).¹

KESIMPTA is intended for patient self-administration with initial guidance from a HCP.

Please refer to the KESIMPTA Summary of Product Characteristics for further information.¹

Watch this video to learn more about how to use KESIMPTA. This will help you teach your patients how to administer KESIMPTA with the Sensoready® pen after the initial dose.



VIDEO

Prescribing Information can be found at the top of the page.

HCP, healthcare professional; RMS, relapsing forms of MS.

Reference

1. KESIMPTA (ofatumumab) Summary of Product Characteristics.

Image



Safety profile

UK | January 2025 | 443398

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL:

<https://www.pro.novartis.com/uk-en/medicines/neuroscience/kesimpta/dosing-and-administration/injection-demo>